Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MG005
- Development stage
- Phase 1
- Lead developer
- Metagone Biotech
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
MG005 is a small molecule inhibitor targeting CRAF (also known as C-Raf kinase), developed by Metagone Biotech. Its primary mechanism of action is the inhibition of CRAF, a serine/threonine-protein kinase involved in the MAPK/ERK signaling pathway, which plays a critical role in cell proliferation and survival. The drug has been investigated primarily for oncology indications, specifically solid tumors. A Phase 1 clinical trial evaluated the safety and preliminary efficacy of MG005 in combination with sorafenib (a multi-kinase inhibitor) in patients with solid tumors[1][2]. The development status remains at Phase 1/Pending.
02
Targets
RAF1 (c-Raf-1 (Y340D/Y341D))
Beyond the preview
Go deeper on MG005.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MG005.